Context: Maternal vitamin D insufficiency has been associated with fetal growth restriction. However, the effect of maternal vitamin D supplementation on fetal growth has not been confirmed.
V itamin D deficiency is emerging as a significant public health problem worldwide in all populations (1) , including newborns, children, adolescents, pregnant women, and the elderly. Studies of pregnant women have shown a high prevalence of maternal deficiency (25- 
hydroxyvitamin D [25(OH)D]
, 50 nmol/L) in the United States (37%) (2) , the United Kingdom (49% to 75%) (3, 4) , and China (70% to 80%) (5, 6) . It is noteworthy that fetal and newborn concentrations of 25(OH)D depend on and correlate with maternal serum levels (7, 8) . Thus, maternal levels of vitamin D during pregnancy determined the vitamin D status at birth and during early life in offspring (9) .
Increasing evidence from observational studies (10) (11) (12) (13) (14) (15) (16) (17) has identified the link between maternal vitamin D deficiency or insufficiency and fetal growth restriction. A meta-analysis of an observational study reinforced the association between vitamin D deficiency and the risk of small for gestational age (SGA) (18) . Despite these findings, the translation to clinical practice has not occurred. In China, most obstetricians are unaware of the vitamin D content in prenatal vitamins. Current evidence on maternal vitamin D status and fetal growth restriction derives largely from observational studies, but small supplementation studies. Understanding of the clinical importance and implications of maternal vitamin D supplement is limited.
A previous placebo-controlled randomized trial conducted .30 years ago demonstrated that maternal vitamin D supplementation at a dose of 1000 IU/d in Asian women during the third trimester led to a nonsignificant reduction in the rate of SGA (19) . A Cochrane Review (20) published in 2012 reported that data from three trials involving 463 women suggested that pregnant women who receive vitamin D supplements less frequently had a baby with lower birth weight than those receiving no treatment or placebo; statistical significance was borderline [relative risk, 0.48; 95% confidence interval (CI), 0.23, 1.01]. From these limited data, the Cochrane Review concluded that there was insufficient evidence to evaluate the effects of vitamin D supplementation during pregnancy (20) . Since then, few studies have addressed this issue and the results have been mixed (7, (21) (22) (23) . The controversial findings may be due to variations of study designs, including the gestational weeks, dose, season, and adherence of maternal vitamin D supplementation as well as ethnicity of the study population.
A 2010 review of the vitamin D requirements by the Institute of Medicine (IOM) resulted in a revised recommended daily allowance of 600 IU/d of vitamin D for women during pregnancy (24) . However, the effect of maternal vitamin D supplementation with 600 IU/d on fetal growth has not been evaluated in China. In this study, we examined the effect of vitamin D supplementation according to the new recommendation of the IOM during the second and third trimester in Chinese pregnant women on cord blood levels of 25(OH)D, calcium, and phosphorus and the risk of SGA.
Subjects and Methods

Study populations and design
As part of the China-Anhui Birth Cohort study (25) , this study was undertaken based on a prospective birth cohort including 2552 married pregnant women enrolled from January to September 2008 in Hefei (32°N latitude). Pregnant women who received prenatal checkups in Hefei Maternal and Child Health Hospital were required to complete a structured questionnaire that included sociodemographic characteristics and lifestyle. At birth, the newborn's anthropometric details and cord blood were collected by study nurses. To remove potential confounding factors in possible maternal medical risks, the following exclusion criteria were applied: stillbirth (n = 11), birth defect (n = 12), women with delivery before 32 weeks of gestation (n = 14), pregnancy with assisted reproductive technology (n = 6), or multiple gestations (n = 48). We finally obtained full data, including cord blood from 1491 motherinfant pairs. The study was approved by the Ethics Committee of the Anhui Medical University, and informed consent was obtained from each participant.
Maternal vitamin D supplementation
When participants first received prenatal checkups in obstetrics clinics, they were routinely advised to take 600 IU/d of vitamin D 3 supplementation during the second and third trimesters. Pregnant women were requested to bring back used commercial vitamin D bottles to receive guidance for the dose of supplementation at subsequent antenatal checkups. At the last visit before delivery, each participant was invited to report the duration and dose of vitamin D supplementation. It was assessed with the question, "How long have you taken vitamin D during pregnancy?" However, most pregnant women could not report the exact dose of vitamin D supplementation. According to participants' reports on the commercial vitamin D supplementation, the dose ranged from 400 to 600 IU/d. For analytic purposes, the duration of vitamin D supplementation was categorized as follows: no use of vitamin D (nonsupplemented group), using vitamin D for ,2 months (supplement group A), and using vitamin D for .2 months (supplement group B).
Cord blood 25(OH)D, calcium, and phosphorus
After delivery, midwives immediately collected cord blood samples and anticoagulated them by using sodium heparin. Plasma samples were centrifuged and promptly refrigerated at 24°C, within 12 hours, and transferred to 280°C freezers for long-term storage. Concentrations of 25(OH)D were measured by using commercial radioimmunoassay kits (DiaSorin, Stillwater, MN), and quantitative outcomes were obtained. Intra-assay and interassay coefficients of variation were 8.8% and 11.1%, respectively. Plasma calcium and phosphorus were measured by standard autoanalyzer methods (Beckman-AU680; Beckman Coulter, Brea, CA). Cord blood concentrations of 25(OH)D were analyzed as a continuous variable and were categorized as ,50 nmol/L (deficiency) and $50 nmol/L (26), as recommended by the Canadian Pediatric Society (27) .
SGA
The primary outcomes for this analysis were based on SGA defined as birth weight , the 10th percentile of distribution for gestational age and on infant sex (28) . Birth weight was measured by study nurses at birth. The accuracy of scales used to measure birth weight was checked using standard weights at the beginning of the study and every 3 months thereafter. The gestational age (in completed weeks) was calculated based on the difference between the date of the last menstrual period and the date of delivery, which were obtained from hospital records.
Covariates
The most important potential confounders were season of birth, prepregnancy body mass index (BMI), and maternal gestational weight gain (GWG) because of their known associations with both plasma 25(OH)D levels (16) and fetal growth (29) . Other potential confounding variables included maternal sociodemographic characteristics (age, education, and household income), prepregnancy lifestyle (alcohol consumption and smoking), food intake frequency during pregnancy (milk and eggs), health status (parity and complication of pregnancy), and birth outcomes (gestational weeks and infant sex), which were assessed through the interview or the medical records. Season of birth was designated as winter (December, January, February), spring (March, April, May), summer (June, July, August), or fall (September, October, November). Prepregnancy BMI was calculated on the basis of the height routinely measured at the clinic visit and on the self-reported prepregnancy weight obtained at interview and were divided into underweight (,18.5), normal weight (18.5 to 23.9), or overweight or obese ($24.0) (30) . The weight gain throughout pregnancy was determined by the difference between the prepregnancy weight and the measured weight recorded at the last prenatal visit before delivery, which was categorized as insufficient, normal, and excessive weight gain based on the recommendation for maternal weight gain in Chinese women (31) . Complications of pregnancy included diabetes mellitus, hypertension, abnormal heart function, glandula thyreoidea disease, intrahepatic cholestasis of pregnancy, and moderate and severe anemia.
Statistical analysis
The demographics and clinical characteristics of the study population were described according to maternal vitamin D supplementation status. We tested for trends across maternal vitamin D supplementation status for each of the characteristics by using linear regression or the Kruskal-Wallis test for continuous variables and Mantel-Haenszel x 2 test or a nonparametric test for trends based on the WilcoxonMann-Whitney test for categorical variables. Differences in cord blood concentrations of 25(OH)D according to characteristics of the mother-infant were evaluated using linear regression models, and b coefficients and 95% CIs were generated.
We examined the differences in cord blood concentrations of 25(OH)D among three groups of maternal vitamin supplementation using multiple linear models, and the nonsupplementation group was regarded as the reference. To reduce the influence of covariates on plasma concentrations of 25(OH)D, we examined levels of 25(OH)D in four ways: (1) unadjusted, (2) adjusted for season of birth, (3) additionally adjusted for prepregnancy BMI and GWG, and (4) additionally adjusted for maternal sociodemographic characteristics (age, education, income), prepregnancy lifestyle (maternal alcohol consumption, father smoking, and alcohol consumption), food intake during pregnancy (milk and eggs), health status (parity and complication of pregnancy), and birth outcomes (gestational weeks and infant sex). The risks of neonatal vitamin D deficiency were assessed by using multiple logistic regression models after adjustment for confounders as described above, and the odds ratios (ORs) and 95% CIs were generated.
Seasonal patterns of 25(OH)D concentration in cord blood for neonates among three groups of maternal vitamin D supplementation were assessed by linear regression models. Multiple logistic regression analysis was performed to determine the effect of maternal vitamin D supplementation on the risk of subsequent SGA with adjustment for confounders. The effect of birth seasons on the fetal growth was furtherly identified through stratification analysis. We also investigated the association of cord blood 25(OH)D with calcium and phosphorus through using linear regression models. We performed all analyses by using SPSS 21.0.
Results
Attrition analyses showed that there were no differences between nonparticipants and participants in the distributions of sociodemographic characteristics, health status, food intake, lifestyle, and birth outcomes.
The characteristics of the study population are shown in Table 1 . Of 1491 mother-infant pairs in this analysis, 21.7% were not using any vitamin D supplementation during pregnancy, 30.6% were using vitamin D supplementation for ,2 months, and 47.7% were using vitamin D supplementation for .2 months. Pregnant women with higher social economic status, primipara, and male infants tended to have a longer duration of vitamin D supplementation. Increasing duration of maternal vitamin D supplementation was significantly related with the higher intake frequency of eggs and milk, as well as more GWG, gestational weeks, and birth weight (P , 0.05 for the trend). The mean cord blood concentration of 25(OH)D among 1491 newborns was 39.4 nmol/L (standard deviation of 20.4), ranging from 6.1 to 119.6 nmol/L. Overall, 75.2% of neonates had 25(OH)D levels of ,50 nmol/L, and only 24.8% had levels of $50 nmol/L. The mean cord blood concentration of 25(OH)D significantly increased across the three groups, but there was no significant difference for the concentration of calcium and phosphorus among the three groups.
The associations of plasma 25(OH)D concentration in cord blood with characteristics of mother-infant pairs in bivariate analyses are shown in Table 2 . Higher cord blood concentrations of 25(OH)D were observed in the pregnant women with insufficient GWG, absent complication of pregnancy and prepregnancy alcohol consumption of husband, as well as delivery at spring, summer, or autumn.
Mean cord blood concentrations of 25(OH)D were 3.9 nmol/L (95% CI, 1.2, 6.5) higher in neonates whose mother took vitamin D supplementation .2 months compared with those whose mother did not take any supplementation (Fig. 1A) . This difference remained significant when adjusted for season of birth (adjusted b = 3.8; 95% CI, 1.2, 6.4), when additionally adjusted for prepregnancy BMI and GWG (adjusted b = 4.1; 95% CI, 1.5, 6.7), and when additionally adjusted for maternal sociodemographic characteristics, prepregnancy lifestyle, health status, and birth outcomes (adjusted b = 3.5; 95% CI, 0.8, 6.2). Consistently, compared with women without any vitamin D supplementation, the proportion of neonatal vitamin D deficiency was significantly lower (79.9% vs 72.3%, P , 0.01) and the adjusted OR was 0.61 (95% CI, 0.43, 0.86) in women with vitamin D supplementation for .2 months (Fig. 1B) . However, the mean cord blood levels of 25(OH)D in women with vitamin D supplementation for ,2 months was not significantly different with that in women without any vitamin D supplementation.
Seasonal variation in vitamin D status is evident with seasonal variation being comparable in all three groups (Fig. 2) . With stratification according to the seasons, the cord blood concentrations of 25(OH)D during winter (adjusted b = 3.4; 95% CI 0.6, 6.3), spring (adjusted b = 3.8; 95% CI, 0.8, 6.9), summer (adjusted b = 6.6; 95% CI, 3.0, 10.3), and autumn (adjusted b = 6.0; 95% CI, 2.3, 9.6) in neonates whose mother took vitamin D supplementation for .2 months were both significantly higher than that in neonates whose mother did not take any vitamin D supplementation. However, there were no differences between women with vitamin D supplementation for ,2 months and women without any vitamin D supplementation in the mean levels of cord blood 25(OH)D according to the seasons. We further investigated the effect of birth seasons on fetal growth. There was no significant difference in the incidence of SGA among the birth seasons across three groups. Despite that neonates in the nonsupplemented group who were born in the summer/autumn had higher mean levels of 25(OH)D than neonates in the supplemented group B who were born in the winter/spring (46.0 618.3 nmol/L vs 29.0 6 14.0 nmol/L, P , 0.001), the incidence of SGA in the nonsupplemented group and those born in the summer/autumn was still significantly increased compared with those in supplemented group B and those born in the winter/spring (12.4% vs 7.6%, P = 0.020). Additionally, we investigated the association of 25(OH)D with calcium and phosphorus in cord blood. The slight but significant linear relationships of 25(OH)D with calcium (r = 0.126, P , 0.001) and phosphorus (r = 0.071, P = 0.006) were observed in all neonates (Supplemental Fig. 1 ).
Discussion
To date, there was little evidence on the association of prenatal vitamin D supplementation with fetal growth from the developing country. This study presents evidence about the effects of maternal vitamin D supplementation on cord blood concentrations of 25(OH)D and the risk of SGA in Chinese population. Although the effect is relatively modest, fetal growth restriction remains the main contributor to mortality of infants and young children in developing countries (32) , which have higher infant mortality and half of the global population. Consequently, the findings were associated with significant and clinical importance. compared to women without any vitamin D supplementation were assessed by using multiple linear regression models and logistic regression models, respectively. Model 1 is unadjusted; model 2 is adjusted for season of birth; models 3 and 4 are additionally adjusted for prepregnancy BMI and GWG and for maternal sociodemographic characteristics, prepregnancy lifestyle, food intake during pregnancy, health status and birth outcomes, respectively. There is no consensus on the optimal dose of vitamin D supplementation during pregnancy, although a 2010 review of the vitamin D requirements by the IOM resulted in a revised recommended daily allowance of 600 IU/d of vitamin D for women during pregnancy (24) . The finding of this study suggested that neonates whose mother took 400 to 600 IU daily of vitamin D supplementation for 2 months had a slight but significant increase (10.1% higher) in 25(OH)D levels at birth and the proportion of vitamin D deficiency (, 50nmol/L) was reduced, compared with those whose mother did not take any vitamin D supplementation. However, .70% of neonates whose mother took 400 to 600 IU daily of vitamin D supplementation were still vitamin D deficient at birth. Given the association of sufficient neonatal vitamin D with a reduced risk of skeletal (23) and nonskeletal health disorders (33), the optimal level seems to be greater than the current dietary reference intake of 600 IU/d.
Several previous observational studies showed that maternal or fetal vitamin D levels in the upper range were linked to the increased risk of fetal growth restriction (12) , smaller head circumference (34) , and schizophrenia (35) in human offspring. These observational findings suggested that caution is necessary with regard to higher levels of prenatal vitamin D supplementation. However, new evidence from well-designed randomized controlled trial (RCT) studies indicated that maternal vitamin D supplementation with $4000 IU of vitamin D has great benefit and is safe (36) . Vitamin D supplementation of 4000 IU/d for pregnant women is most effective in achieving sufficiency in all women and their neonates (22, 37) . The great benefits on reducing risk of maternal comorbidities and improving neonatal outcomes have been reported in several RCT studies (21, (38) (39) (40) (41) , and the long-term effect of prenatal vitamin D supplementation on asthma or recurrent wheezing in offspring by age 3 years also has been observed (42, 43) . Inconsistently, a few RCT studies with prenatal $4000 IU/d vitamin D supplementation have not found significant effects on anthropometric measurements of infants at birth and at 12 months of age (7, 22, 23) . Therefore, larger and longer follow-up RCT studies including more diverse race/ethnic participants are needed to determine the optimal dose of prenatal vitamin D supplementation.
Our study suggested that the slight but significantly increased fetal levels of 25(OH)D owing to the 400 to 600 IU/d vitamin D supplementation during pregnancy may essentially contribute to the improvement of fetal growth. However, many of today's practicing obstetricians in China are not aware of the vitamin D content in prenatal vitamins. Most pregnant women did not receive the recommendation about supplementation for vitamin D during pregnancy. Alternativley, in China, pregnant women pay for vitamin D supplements directly out of pocket. Additional vitamin D supplementation during the whole pregnancy increases the family financial burden, which will affect the ability of pregnant women to receive vitamin D supplementation. In our findings, more than half of the participants could not adhere to supplementation for 2 months during pregnancy. Therefore, it is a reasonable and cautious strategy in the current developing countries to stepwise increase routine vitamin D supplementation levels from 600 IU/d according the current recommendation by IOM to 4000 IU/d based on the evidence of new RCT studies. Additionally, integrated intervention including enhancing the awareness of vitamin D in health workers, adding vitamin D into the national reimbursement drug inventory, and fortification of food with vitamin D could further improve the intake of vitamin D in the developing countries.
Although we observed a significant linear relationships of 25(OH)D with calcium and phosphorus in cord blood, the mean levels of calcium and phosphorus between the nonsupplemented group and the supplemented group had no difference. Thus, the regulation of 25(OH)D on fetal skeletal metabolism of calcium and phosphorus was unlikely associated with the improvement of fetal growth observed in this study. The roles of a low dose of vitamin D supplementation on placental function, metabolism of glucose and lipids, and inflammation and genomic alterations should get more attention (15, 44, 45) .
Unexpectedly, our study showed that the incidence of SGA of neonates in the nonsupplemented group and born in the summer/autumn, whose 25(OH)D was in the highest levels across seasons, was still significantly increased compared with those in the supplemented group B and born in the winter/spring. The finding suggested that birth season is a critical predictor for fetal 25(OH)D at birth, but not for fetal growth. The neonates in the nonsupplemented group had the lowest levels of 25(OH)D in any season (even in the summer) compared with the other two groups in the same season. These results indicate that the fetuses in the nonsupplemented group might always have lower 25(OH)D levels during the whole pregnancy than do fetuses in the supplemented group. Thus, we thought that the improvement in fetal growth observed in this study should be largely attributed to the maternal vitamin D supplementation during the pregnancy instead of the seasonal 25(OH)D levels at birth.
The prospective study design, relatively large sample size, strict selection criteria for the participants, statistical adjustments for several potential confounding factors such as food intake during pregnancy, GWG, and season of birth add credence to our data. Unlike rigorous clinical supplement trials, this study was designed to focus on the natural behavior of vitamin D supplementation during pregnancy. We are limited in our ability to strongly control the compliance of vitamin D supplementation. Therefore, the duration of supplementation in this study was used to reflect the compliance of vitamin D supplementation. Individual variations of duration and dose among pregnant women with vitamin D supplementation for .2 months may slightly fluctuate the association descripted in this study. Additionally, we also could not exclude the effect of other supplementations such as calcium.
The findings in this study suggest that maternal vitamin D supplementation during pregnancy as recommended by the IOM resulted in slight but significantly higher fetal levels of 25(OH)D and essentially improved fetal growth. Further studies need to identify the effects that higher intakes of vitamin D supplementation would have and consequently to construct the appropriate strategies for maternal vitamin D supplementation in developing countries.
